129 related articles for article (PubMed ID: 35316569)
41. Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001.
Athale UH; Puligandla M; Stevenson KE; Asselin B; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Harris MH; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 Oct; 65(10):e27256. PubMed ID: 29878490
[TBL] [Abstract][Full Text] [Related]
42. Thromboembolism in children with cancer: a retrospective multicenter study in Korea.
Choi HS; Kim HJ; Kang HJ; Lee JW; Shin HY; Park HJ; Park BK; Lee YH; Lee JA; Lim YJ; Park KD
J Thromb Thrombolysis; 2019 May; 47(4):558-565. PubMed ID: 30666552
[TBL] [Abstract][Full Text] [Related]
43. Genomic analysis of venous thrombosis in children with acute lymphoblastic leukemia from diverse ancestries.
Zheng Y; Yang W; Estepp J; Pei D; Cheng C; Takemoto CM; Inaba H; Jeha S; Pui CH; Relling MV; Karol SE
Haematologica; 2024 Jan; 109(1):53-59. PubMed ID: 37408475
[TBL] [Abstract][Full Text] [Related]
44. Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis: an AIEOP experience.
Santoro N; Colombini A; Silvestri D; Grassi M; Giordano P; Parasole R; Barisone E; Caruso R; Conter V; Valsecchi MG; Masera G; Rizzari C
J Pediatr Hematol Oncol; 2013 Jul; 35(5):348-55. PubMed ID: 23619106
[TBL] [Abstract][Full Text] [Related]
45. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.
Vrooman LM; Neuberg DS; Stevenson KE; Asselin BL; Athale UH; Clavell L; Cole PD; Kelly KM; Larsen EC; Laverdière C; Michon B; Schorin M; Schwartz CL; Cohen HJ; Lipshultz SE; Silverman LB; Sallan SE
Eur J Cancer; 2011 Jun; 47(9):1373-9. PubMed ID: 21514146
[TBL] [Abstract][Full Text] [Related]
46. Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based Regimens.
Patel JN; Robinson M; Jagosky M; Slaughter D; Arnall J; Jandrisevits E; Matusz-Fisher A; Atrash S; Paul B; Bhutani M; Voorhees P; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):188-198.e2. PubMed ID: 33339769
[TBL] [Abstract][Full Text] [Related]
47. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy.
Athale UH; Chan AK
Thromb Res; 2003; 111(4-5):199-212. PubMed ID: 14693164
[TBL] [Abstract][Full Text] [Related]
48. Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment.
Harlev D; Zaidman I; Sarig G; Ben Arush MW; Brenner B; Elhasid R
Thromb Res; 2010 Aug; 126(2):93-7. PubMed ID: 20546854
[TBL] [Abstract][Full Text] [Related]
49. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin.
Elliott MA; Wolf RC; Hook CC; Pruthi RK; Heit JA; Letendre LL; Tefferi A; Kaufmann SH; Mesa RA; Litzow MR
Leuk Lymphoma; 2004 Aug; 45(8):1545-9. PubMed ID: 15370205
[TBL] [Abstract][Full Text] [Related]
50. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
Couturier MA; Huguet F; Chevallier P; Suarez F; Thomas X; Escoffre-Barbe M; Cacheux V; Pignon JM; Bonmati C; Sanhes L; Bories P; Daguindau E; Dorvaux V; Reman O; Frayfer J; Orvain C; Lhéritier V; Ifrah N; Dombret H; Hunault-Berger M; Tanguy-Schmidt A
Am J Hematol; 2015 Nov; 90(11):986-91. PubMed ID: 26214580
[TBL] [Abstract][Full Text] [Related]
51. Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia.
Prasca S; Carmona R; Ji L; Ko RH; Bhojwani D; Rawlins YA; Mittelman SD; Young G; Orgel E
Thromb Res; 2018 May; 165():44-50. PubMed ID: 29567586
[TBL] [Abstract][Full Text] [Related]
52. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.
Vrooman LM; Blonquist TM; Harris MH; Stevenson KE; Place AE; Hunt SK; O'Brien JE; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Sulis ML; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
Blood Adv; 2018 Jun; 2(12):1449-1458. PubMed ID: 29941458
[TBL] [Abstract][Full Text] [Related]
53. Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.
Kashanian SM; Holtzman NG; Patzke CL; Cornu J; Duffy A; Koka M; Niyongere S; Duong VH; Baer MR; Apata J; Kamangar F; Emadi A
Cancer Chemother Pharmacol; 2021 Jun; 87(6):817-826. PubMed ID: 33677674
[TBL] [Abstract][Full Text] [Related]
54. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
Smith M; Arthur D; Camitta B; Carroll AJ; Crist W; Gaynon P; Gelber R; Heerema N; Korn EL; Link M; Murphy S; Pui CH; Pullen J; Reamon G; Sallan SE; Sather H; Shuster J; Simon R; Trigg M; Tubergen D; Uckun F; Ungerleider R
J Clin Oncol; 1996 Jan; 14(1):18-24. PubMed ID: 8558195
[TBL] [Abstract][Full Text] [Related]
55. Impact of Socioeconomic Status on Timing of Relapse and Overall Survival for Children Treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000-2010).
Bona K; Blonquist TM; Neuberg DS; Silverman LB; Wolfe J
Pediatr Blood Cancer; 2016 Jun; 63(6):1012-8. PubMed ID: 26913850
[TBL] [Abstract][Full Text] [Related]
56. ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer.
Li D; Pise MN; Overman MJ; Liu C; Tang H; Vadhan-Raj S; Abbruzzese JL
Cancer Med; 2015 Nov; 4(11):1651-8. PubMed ID: 26275671
[TBL] [Abstract][Full Text] [Related]
57. Cerebral sinus venous thrombosis during childhood acute lymphoblastic leukemia therapy: Risk factors and management.
Ghanem KM; Dhayni RM; Al-Aridi C; Tarek N; Tamim H; Chan AKC; Saab R; Abboud MR; El-Solh H; Muwakkit SA
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660695
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.
Sulis ML; Blonquist TM; Stevenson KE; Hunt SK; Kay-Green S; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JG; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 May; 65(5):e26952. PubMed ID: 29319209
[TBL] [Abstract][Full Text] [Related]
59. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration.
Nowak-Göttl U; Ahlke E; Fleischhack G; Schwabe D; Schobess R; Schumann C; Junker R
Blood; 2003 Apr; 101(7):2529-33. PubMed ID: 12517808
[TBL] [Abstract][Full Text] [Related]
60. Thromboembolism prophylaxis during L-asparaginase therapy in acute lymphoblastic leukemia - time to reconsider current approaches?
Fulcher J; Carrier M
Thromb Res; 2020 Apr; 188():100-102. PubMed ID: 32120278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
